The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

ABSTRACT:

Background/aim

Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition in myelofibrosis is associated with an elevated frequency of aggressive B-cell lymphomas. However, the biological basis and significance of this pharmacobiological adverse event is unknown. The aim of this bioinformatics study is to detect any possible confounding effects of ruxolitinib on the genesis of lymphoproliferative disorders.

Materials and methods

The gene expression data were retrieved from the E-MTAB-783 Cancer Ge

SUBMITTER: Turk C 

PROVIDER: S-EPMC7018380 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature